Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To analyze the incidence and associated factors of hypothyroidism after radioiodine treatment for hyperthyroidism during a 13-year follow-up period.

Subjects And Methods: This was a retrospective study of consecutive patients with hyperthyroidism who were treated using a single dose of radioactive iodine (RAI) with a calculated dose regimen from 07/2005 to 12/2012. Univariate and multivariate Cox regression models were used to examine the factors that are associated with the occurrence of hypothyroidism after RAI therapy. Kaplan-Meier analysis was used for confirming associations between these models.

Results: A total of 182 patients were included during a 7.5-year median follow-up (range: 6-13 years). They were 36.4±11.1 years. The mean radioactive iodine dosage was 308.2±104.3 (range: 129.5-740.0) MBq. The rates of euthyroidism, early hypothyroidism, improvement, and ineffective treatment at 6 months were 48.4%, 37.9%, 8.8%, and 4.9%, respectively. The cumulative incidence of hypothyroidism in all patients with hyperthyroidism was 45.6% at 1 year, 48.9% at 5 years, and 52.3% at 10 years. Thyroid weight >46g (HR=0.643, 95%CI: 0.422-0.981, P=0.040) and a course of disease of 0.5-3 years (HR=0.592, 95%CI: 0.358-0.981, P=0.042) were identified as independent factors associated with an increased risk of hypothyroidism after radioactive iodine therapy.

Conclusion: Radioactive iodine treatment with a calculated dose has a high cure rate for hyperthyroidism and has a low annual increase of hypothyroidism. Hypothyroidism after radioactive iodine treatment is more likely to occur in patients with small thyroid and a short disease course.

Download full-text PDF

Source
http://dx.doi.org/10.1967/s002449912433DOI Listing

Publication Analysis

Top Keywords

radioactive iodine
20
patients hyperthyroidism
12
calculated dose
8
factors associated
8
hypothyroidism radioactive
8
iodine treatment
8
hypothyroidism
7
years
6
patients
5
hyperthyroidism
5

Similar Publications

High risk factors, molecular features and clinical management for radioactive iodine-refractory differentiated thyroid carcinoma.

Front Oncol

August 2025

Department of Pathology, Institute of Clinical Pathology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Despite the generally favorable prognosis of differentiated thyroid carcinoma (DTC) following surgery and radioactive iodine (RAI) therapy, approximately 10% of cases eventually develop resistance to RAI. This condition, known as radioiodine-refractory differentiated thyroid carcinoma (RAIR-DTC), is associated with a poor prognosis, with a 10-year survival rate of only 10% from the time of metastasis detection. The limited availability of safe and effective alternative treatments poses a significant challenge to clinical management.

View Article and Find Full Text PDF

Thyroglossal duct carcinoma is a rare clinical condition, accounting for only 1% of operated cases. It is characterized by ectopic thyroid adenocarcinoma developing within thyroglossal duct cysts (TGDCs). Among these, papillary thyroid carcinoma is the most frequently reported pathological type.

View Article and Find Full Text PDF

Ferroptosis-Enhanced Radiopharmaceutical Therapy via a Manganese-Based Nanoplatform.

Mol Pharm

September 2025

Department of Nuclear Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China.

Radiopharmaceutical therapy (RPT) is a therapeutic strategy that delivers radionuclides in a targeted manner to achieve precise radiation-induced killing of tumor cells. While RPT primarily induces tumor cell death through apoptosis, resistance to apoptosis has been identified as a key mechanism underlying the radioresistance. Therefore, integrating nonapoptotic cell death pathways with RPT offers a promising strategy to enhance its therapeutic efficacy.

View Article and Find Full Text PDF

Struma ovarii (SO) is a rare form of ovarian teratoma predominantly composed of thyroid tissue. While most cases follow a benign course, some may exhibit malignant transformation or extra-ovarian spread. We present the case of a 43-year-old woman with a history of SO previously treated with right oophorectomy and systemic chemotherapy, along with a separate diagnosis of papillary thyroid carcinoma managed with total thyroidectomy and radioactive iodine ablation.

View Article and Find Full Text PDF